Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [
[11C]PBR28
microglia
multiple system atrophy
positron emission tomography
translocator protein
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
06
09
2021
received:
04
05
2021
accepted:
10
09
2021
pubmed:
6
10
2021
medline:
17
3
2022
entrez:
5
10
2021
Statut:
ppublish
Résumé
The clinical diagnosis of multiple system atrophy (MSA) is challenged by overlapping features with Parkinson's disease (PD) and late-onset ataxias. Additional biomarkers are needed to confirm MSA and to advance the understanding of pathophysiology. Positron emission tomography (PET) imaging of the translocator protein (TSPO), expressed by glia cells, has shown elevations in MSA. In this multicenter PET study, we assess the performance of TSPO imaging as a diagnostic marker for MSA. We analyzed [ We observed a conspicuous pattern of elevated regional [ We found a pattern of significantly increased regional glial TSPO binding in patients with MSA. Intriguingly, our data are in line with severe neuroinflammation in MSA. Glia imaging may have potential to support clinical MSA diagnosis and patient stratification in clinical trials on novel drug therapies for an α-synucleinopathy that remains strikingly incurable. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
The clinical diagnosis of multiple system atrophy (MSA) is challenged by overlapping features with Parkinson's disease (PD) and late-onset ataxias. Additional biomarkers are needed to confirm MSA and to advance the understanding of pathophysiology. Positron emission tomography (PET) imaging of the translocator protein (TSPO), expressed by glia cells, has shown elevations in MSA.
OBJECTIVE
In this multicenter PET study, we assess the performance of TSPO imaging as a diagnostic marker for MSA.
METHODS
We analyzed [
RESULTS
We observed a conspicuous pattern of elevated regional [
CONCLUSIONS
We found a pattern of significantly increased regional glial TSPO binding in patients with MSA. Intriguingly, our data are in line with severe neuroinflammation in MSA. Glia imaging may have potential to support clinical MSA diagnosis and patient stratification in clinical trials on novel drug therapies for an α-synucleinopathy that remains strikingly incurable. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Substances chimiques
Receptors, GABA
0
TSPO protein, human
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-129Informations de copyright
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
Watanabe H, Riku Y, Hara K, et al. Clinical and imaging features of multiple system atrophy: challenges for an early and clinically definitive diagnosis. J Mov Disord 2018;11:107-120.
Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med 2015;372:249-263.
Stankovic I, Quinn N, Vignatelli L, et al. A critique of the second consensus criteria for multiple system atrophy. Mov Disord 2019;34:975-984.
Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 2015;85:404-412.
Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 2009;24:2272-2276.
Meissner WG, Fernagut PO, Dehay B, et al. Multiple system atrophy: recent developments and future perspectives. Mov Disord 2019;34:1629-1642.
Yamasaki R, Yamaguchi H, Matsushita T, Fujii T, Hiwatashi A, Kira J-I. Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study. J Neuroinflammation 2017;14:89.
Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T. Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 2004;63:43-52.
Salvesen L, Ullerup BH, Sunay FB, et al. Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy - a stereological study. Neurobiol Dis 2015;74:104-113.
Gerhard A, Banati RB, Goerres GB, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003;61:686-689.
Kübler D, Wächter T, Cabanel N, et al. Widespread microglial activation in multiple system atrophy. Mov Disord 2019;34:564-568.
Jucaite A, Svenningsson P, Rinne JO, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain 2015;138(Pt 9):2687-2700.
Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012;32:1-5.
Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004;19:1391-1402.
Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22:41-47.
Briard E, Zoghbi SS, Imaizumi M, et al. Synthesis and evaluation in monkey of two sensitive 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J Med Chem 2008;51:17-30.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
Keuken MC, Bazin PL, Crown L, et al. Quantifying inter-individual anatomical variability in the subcortex using 7 T structural MRI. Neuroimage 2014;94:40-46.
Cselényi Z, Olsson H, Halldin C, Gulyás B, Farde L. A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635. Neuroimage 2006;32:1690-1708.
Tuisku J, Plavén-Sigray P, Gaiser EC, et al. Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study. Eur J Nucl Med Mol Imaging 2019;46:2329-2338.
Habeck C, Stern Y, Alzheimer's Disease Neuroimaging Initiative. Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease. Cell Biochem Biophys 2010;58:53-67.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971;76:378-382.
Nykjaer CH, Brudek T, Salvesen L, Pakkenberg B. Changes in the cell population in brain white matter in multiple system atrophy. Mov Disord 2017;3:1074-1082.
Cosenza-Nashat M, Zhao ML, Suh HS, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009;35:306-328.
Lavisse S, Guillermier M, Hérard AS, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 2012;32:10809-10818.
Hoffmann A, Ettle B, Battis K, et al. Oligodendroglial α-synucleinopathy-driven neuroinflammation in multiple system atrophy. Brain Pathol 2019;29:380-396.
Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 2007;71:1291-1303.
Valdinocci D, Radford RAW, Goulding M, Hayashi J, Chung RS, Pountney DL. Extracellular interactions of alpha-Synuclein in multiple system atrophy. Int J Mol Sci 2018;19:4129.
Tong J, Wong H, Guttman M, et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 2010;133:172-188.
Lyoo CH, Ikawa M, Liow JS, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect Neuroinflammation measured with PET Radioligand binding to Translocator protein. J Nucl Med 2015;56:701-706.
Goebel G, Seppi K, Donnemiller E, et al. A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. Eur J Nucl Med Mol Imaging 2011;38:702-710.
Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9:149-158.
Archer DB, Bricker JT, Chu WT, et al. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multi-site machine learning study. Lancet Digit Health 2019;1:e222-e231.
Krismer F, Beliveau V, Seppi K, et al. Automated analysis of diffusion-weighted magnetic resonance imaging for the differential diagnosis of multiple system atrophy from Parkinson's disease. Mov Disord 2021;36:241-245.
Péran P, Barbagallo G, Nemmi F, et al. MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy. Mov Disord 2018;33:600-608.
Vergnet S, Hives F, Foubert-Samier A, et al. Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism Relat Disord 2019;63:199-203.
Gu SC, Ye Q, Yuan CX. Metabolic pattern analysis of 18F-FDG PET as a marker for Parkinson's disease: a systematic review and meta-analysis. Rev Neurosci 2019;30:743-756.
Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 2005;20(suppl 12):S29-S36.
Kreisl WC, Kim MJ, Coughlin JM, Henter ID, Owen DR, Innis RB. PET imaging of neuroinflammation in neurological disorders. Lancet Neurol 2020;19:940-950.
Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 2006;21:89-93.
Gerhard A, Watts J, Trender-Gerhard I, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 2004;19:1221-1226.
Ghadery C, Koshimori Y, Coakeley S, et al. Microglial activation in Parkinson's disease using [18F]-FEPPA. J Neuroinflammation 2017;14:8.
Koshimori Y, Ko JH, Mizrahi R, et al. Imaging striatal microglial activation in patients with Parkinson's disease. PLoS One 2015;10:e0138721.
Varnäs K, Cselényi Z, Jucaite A, et al. PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. Eur J Nucl Med Mol Imaging 2019;46:367-375.
Ikawa M, Lohith TG, Shrestha S, et al. 11C-ER176, a Radioligand for 18-kDa Translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain. J Nucl Med 2017;58:320-325.